Eisai Looks To New Drugs, Sales Expansions To Supplant Aricept Patent
This article was originally published in PharmAsia News
Eisai expects product launches and increased sales of existing drugs to help it survive the loss of U.S. patent protection for its best-selling Aricept (donepezil) Alzheimer's disease drug later this year
You may also be interested in...
An independent data monitoring committee gives Eisai the green light to complete enrollment for its Phase III ACCESS trial of Eritoran (tetrasodium) to treat severe sepsis. As part of a planned interim analysis, the board evaluated the efficacy and safety of the first 1,500 patients in the placebo-controlled trial, and recommended enrollment continue to the 2,000-patient goal after finding no safety concerns. The ACCESS trial targets a population with severe sepsis that has a moderate to high risk of mortality as determined by baseline APACHE II scores from 21 to 37 - APACHE II is a severity of illness scoring system commonly used in sepsis research. Though sepsis has proven to be a difficult development path (Lilly's Xigris is the only approved treatment), the go-ahead is a good sign for Eisai, which is counting on future Eritoran sales to offset the Aricept patent loss (1PharmAsia News, March 5, 2010)
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.